Alkem Laboratories gets USFDA warning letter for Daman facility
In short
Alkem Laboratories got a USFDA warning letter for its Daman facility and was classified as OAI. The company said it will reply to the regulator within the given timeline.
It also said the facility keeps making and supplying approved products to the US market.
What the reporting says
Alkem Laboratories received a USFDA warning letter and an OAI classification for its Daman facility, according to the headline and summary provided. The company said it will respond to the USFDA within the stipulated timeline. It also said it continues to manufacture and supply approved products from the facility to the US market, indicating ongoing operations despite the regulatory action.
Why it matters
Alkem Laboratories received a USFDA warning letter with OAI classification for its Daman facility. The company said it will respond within the stipulated timeline and that the facility continues to manufacture and supply approved products to the US market. The regulatory notice is relevant for Alkem’s US-facing operations and may keep investors focused on compliance and supply continuity.